4.8 Article

Interplay between TRAP1 and Sirtuin-3 Modulates Mitochondrial Respiration and Oxidative Stress to Maintain Stemness of Glioma Stem Cells

期刊

CANCER RESEARCH
卷 79, 期 7, 页码 1369-1382

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-18-2558

关键词

-

类别

资金

  1. National Cancer Center (Republic of Korea) [NCC-1810121-1]
  2. UNIST research fund (Republic of Korea) [1.180018.01]
  3. National Research Foundation of Korea (NRF) - MSIT [NRF-2016R1A2B2012624, NRF-2016R1A6A3A11934753, NRF-2017R1A2B4011741, NRF-2017R1D1A1B03033303, NRF-22A20130012280, NRF-2018R1A5A1024340, NRF-2018R1A4A1025860]
  4. Korea Drug Development Fund (KDDF) - MSIT, Republic of Korea [KDDF-201512-02]
  5. Korea Drug Development Fund (KDDF) - MOTIE, Republic of Korea [KDDF-201512-02]
  6. Korea Drug Development Fund (KDDF) - MOHW, Republic of Korea [KDDF-201512-02]
  7. Korea Evaluation Institute of Industrial Technology (KEIT) [KDDF-201512-02] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Glioblastoma (GBM) cancer stem cells (CSC) are primarily responsible for metastatic dissemination, resistance to therapy, and relapse of GBM, the most common and aggressive brain tumor. Development and maintenance of CSCs require orchestrated metabolic rewiring and metabolic adaptation to a changing microenvironment. Here, we show that cooperative interplay between the mitochondrial chaperone TRAP1 and the major mitochondria deacetylase sirtuin-3 (SIRT3) in glioma stem cells (GSC) increases mitochondrial respiratory capacity and reduces production of reactive oxygen species. This metabolic regulation endowed GSCs with metabolic plasticity, facilitated adaptation to stress (particularly reduced nutrient supply), and maintained stemness. Inactivation of TRAP1 or SIRT3 compromised their interdependent regulatory mechanisms, leading to metabolic alterations, loss of stemness, and suppression of tumor formation by GSC in vivo. Thus, targeting the metabolic mechanisms regulating interplay between TRAP1 and SIRT3 may provide a novel therapeutic option for intractable patients with GBM. Significance: Discovery and functional analysis of a TRAP1-SIRT3 complex in glioma stem cells identify potential target proteins for glioblastoma treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Multidisciplinary

Quaternary ammonium-based mitochondria targeting anticancer agents with high water solubility

Sangpil Kim, Nam Gu Yoon, Batakrishna Jana, Byoung Heon Kang, Ja-Hyoung Ryu

Summary: Novel mitochondria targeting agents with high water solubility were designed by introducing quaternary ammonium, which effectively inhibit mitochondrial respiratory chain and induce apoptosis in cancer cells. These agents have the potential to be developed as anticancer drugs.

BULLETIN OF THE KOREAN CHEMICAL SOCIETY (2022)

Article Biochemistry & Molecular Biology

Triphenylphosphonium conjugation to a TRAP1 inhibitor, 2-amino-6--chloro-7,9-dihydro-8H-purin-8-one increases antiproliferative activity

Sujae Yang, Nam Gu Yoon, Min-A Park, Jisu Yun, Jin Young Im, Byoung Heon Kang, Soosung Kang

Summary: TRAP1, overexpressed in many cancer cells, supports tumorigenesis by rewiring vital metabolic and cell death pathways. Compound 6a, a TRAP1-selective inhibitor, shows potent anticancer activity in multiple cancer cell lines and suppresses tumor growth in a nude mouse model.

BIOORGANIC CHEMISTRY (2022)

Article Clinical Neurology

MYB/MYBL1::QKI fusion-positive diffuse glioma

Ye Yoon Suh, Kwanghoon Lee, Yu-Mi Shim, Ji Hoon Phi, Chul-Kee Park, Seung-Ki Kim, Seung Hong Choi, Hongseok Yun, Sung-Hye Park

Summary: The MYB/MYBL1::QKI fusion activates the oncogene MYB and deletes the tumor suppressor gene QKI. Previously, this fusion was only reported in angiocentric glioma (AG) and diffuse low-grade glioma. This study compares two tumors with the MYB/MYBL1::QKI fusion: a diffuse pediatric-type high-grade glioma (DPedHGG) in an 11-year-old boy and an AG in a 46-year-old woman. Characterization using immunohistochemistry, next-generation sequencing, and methylation profiling reveals their molecular characteristics and supports the presence of MYB/MYBL1 alterations in higher-grade gliomas.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2023)

Article Oncology

LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

Aram Ko, Mohammad Hasanain, Young Taek Oh, Fulvio D'Angelo, Danika Sommer, Brulinda Frangaj, Suzanne Tran, Franck Bielle, Bianca Pollo, Rosina Paterra, Karima Mokhtari, Rajesh Kumar Soni, Matthieu Peyre, Marica Eoli, Laura Papi, Michel Kalamarides, Marc Sanson, Antonio Iavarone, Anna Lasorella

Summary: LZTR1 is a substrate-specific adaptor of a CUL3-dependent ubiquitin ligase frequently mutated in cancer. The study identified EGFR and AXL as LZTR1 substrates targeted for degradation, and found that LZTR1 mutations result in the accumulation and deregulated signaling of EGFR and AXL. The study also revealed vulnerabilities of LZTR1-mutant tumors to inhibition of EGFR and AXL, providing precision targeting for patients with LZTR1-mutant cancer.

CANCER DISCOVERY (2023)

Article Genetics & Heredity

Fc gamma receptor IIb in tumor-associated macrophages and dendritic cells drives poor prognosis of recurrent glioblastoma through immune-associated signaling pathways

Xiong Jin, Jianlei Kang, Qing Lu, Shuang-Lei Guo, Meichen Liu, Yue Zhang, Can Cui, Hong-Lin Liu, Xin Xu, Jinlong Yin

Summary: This study identified Fc gamma RIIb as a potential driver for recurrent GBM based on gene expression analysis. Further investigations revealed a highly negative correlation between FCGR2B expression and poor prognosis in patients with recurrent GBM. The study also found that Fc gamma RIIb was strongly associated with immune-related signaling pathways and expressed in tumor-associated macrophages and dendritic cells. These findings provide novel insights into the role of Fc gamma RIIb in recurrent GBM and suggest it as a promising immune therapeutic target.

FRONTIERS IN GENETICS (2023)

Article Multidisciplinary Sciences

IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis

Weiwei Lin, Rui Niu, Seong-Min Park, Yan Zou, Sung Soo Kim, Xue Xia, Songge Xing, Qingshan Yang, Xinhong Sun, Zheng Yuan, Shuchang Zhou, Dongya Zhang, Hyung Joon Kwon, Saewhan Park, Chan Il Kim, Harim Koo, Yang Liu, Haigang Wu, Meng Zheng, Heon Yoo, Bingyang Shi, Jong Bae Park, Jinlong Yin

Summary: The IGFBP5-ROR1/HER2-CREB signaling axis is a potential therapeutic target for glioblastoma (GBM) to inhibit the invasion capacity and gene expression of GBM stem-like cells (GSCs) and suppress tumor growth.

NATURE COMMUNICATIONS (2023)

Article Pharmacology & Pharmacy

The Regulatory Roles of Mitochondrial Metabolism Dynamics and Mitochondria Calcium Uniporter (MCU) in Bevacizumab Resistance of GBM

Yejin Kim, Chulhwan Kwak, Jong Bae Park, Do-Hyun Nam, Hyun-Woo Rhee, Sung Soo Kim

Summary: Adapted oxidative phosphorylation and tricarboxylic acid cycle activations play crucial roles in tumor microenvironments for abnormal energy consumption in cancer development and drug resistance. A longitudinal GBM mouse model with acquired resistance to bevacizumab was established to investigate the molecular mechanism related to mitochondrial metabolic dynamics and drug resistance in GBM. Proteomic analysis revealed enrichment of OXPHOS, TCA, and calcium signaling gene sets in the bevacizumab pre-resistance phase. Additionally, targeting the MCU protein, a pore-forming subunit of the mitochondrial calcium uniporter, showed promising therapeutic potential in combination with bevacizumab in recurrent GBM.

ADVANCED THERAPEUTICS (2023)

Editorial Material Clinical Neurology

Announcing the Asian Oceanian Society of Neuropathology guidelines for Adapting Diagnostic Approaches for Practical Taxonomy in Resource-Restrained Regions (AOSNP-ADAPTR)

M. E. Buckland, C. Sarkar, V. Santosh, M. Al-Hussaini, S. H. Park, T. Tihan, H. K. Ng, T. Komori

BRAIN PATHOLOGY (2023)

Article Clinical Neurology

Fibrous hamartoma of infancy of the spinal cord resembling conus and filum, with a coexisting sacral dimple

Tae-Hwan Park, Kyung Hyun Kim, Seung-Ki Kim, Kyu-Chang Wang, Sung-Hye Park, Ji Yeoun Lee

Summary: Fibrous hamartoma of infancy (FHI) is a rare benign soft tissue lesion that usually occurs in infants and young children within the first 2 years of life. FHI in the central nervous system (CNS) is extremely rare, with only two cases of spinal cord FHI reported so far. We present a unique case of FHI in a 1-month-old girl with a skin dimple in the coccygeal area, where both a skin lesion and an intramedullary mass were diagnosed as FHI. Despite being diagnosed with a neurogenic bladder, the patient maintained normal neurological function and showed good mobility during the 5.5-year follow-up period.

CHILDS NERVOUS SYSTEM (2023)

Review Clinical Neurology

Neuroepithelial tumor with EWSR1::PATZ1 fusion: A literature review

Hyunhee Kim, Kwanghoon Lee, Ji Hoon Phi, Sun Ha Paek, Hongseok Yun, Seung Hong Choi, Sung-Hye Park

Summary: This study presents the clinicopathological and molecular genetic characteristics of a neuroepithelial tumor (NET) with EWSR1::PATZ1 fusion, which has recently been discovered in rare central nervous system tumors and soft tissue sarcomas. Two cases of this fusion were identified, with the pediatric case showing a high-grade tumor and longer survival compared to conventional glioblastoma. The TERT promoter mutation may serve as an indicator of high-grade behavior in PATZ1 fusion NET.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2023)

Article Medicine, Research & Experimental

Epigenetic Alteration of H3K27me3 as a Possible Oncogenic Mechanism of Central Neurocytoma

Hyunhee Kim, Kwanghoon Lee, Yu -Mi Shim, Eric Eunshik Kim, Seung-Ki Kim, Ji Hoon Phi, Chul-Kee Park, Seung Hong Choi, Sung-Hye Park

Summary: Central neurocytoma is a low-grade neuronal tumor that mainly occurs in the lateral ventricle, and the genetic abnormalities that cause this tumor are poorly understood. Through the study of immunomarkers in fetal and adult brains, as well as supratentorial periventricular tumors, the biomarkers, cell of origin, and tumorigenesis of central neurocytoma were characterized. Immunohistochemical analysis showed that central neurocytomas were positive for certain markers, including FGFR3, SSTR2, TTF-1, GLUT-1, and L1CAM.

LABORATORY INVESTIGATION (2023)

Article Biochemistry & Molecular Biology

Enrichment of Deleterious Mutated Genes Involved in Ciliary Function and Histone Modification in Brain Cancer Patient-Derived Xenograft Models

Hyeongsun Jeong, Hyo Eun Moon, Seongmin Yun, Seung Woo Cho, Hye Ran Park, Sung-Hye Park, Kyungjae Myung, Taejoon Kwon, Sun Ha Paek

Summary: In this study, 13 PDX models derived from 11 brain tumor patients were established. It was found that PDX samples were enriched with brain tumor-related genes and had distinct mutation profiles compared to the original tumors, indicating mutational alterations occurring in the xenograft environment.

BIOMEDICINES (2023)

Article Pharmacology & Pharmacy

Translational mRNA Profiling Analysis of Pseudopalisading Cells in Bevacizumab Resistance of GBM

Yejin Kim, Tae Hoon Kim, Srun Sreynet, Yong Seok Oh, Do-Hyun Nam, Jong Bae Park, Sung Soo Kim

Summary: This study conducted a translatomic analysis on pseudopalisading cells in brain tumors and found that these cells are associated with neurodegenerative diseases. The results of this study provide important insights into the molecular mechanism of resistance induced by bevacizumab treatment.

ADVANCED THERAPEUTICS (2023)

Review Medicine, General & Internal

Brain Tumor Classification by Methylation Profile

Jin Woo Park, Kwanghoon Lee, Eric Eunshik Kim, Seong-Ik Kim, Sung-Hye Park

Summary: The methylation classifier is a tool used to accurately classify brain tumors based on their methylation profiles. It helps healthcare professionals predict tumor prognosis and establish personalized treatment plans. However, it has limitations in classifying all types of brain tumors and faces challenges in obtaining reference data and charging patients for its services.

JOURNAL OF KOREAN MEDICAL SCIENCE (2023)

暂无数据